Literature DB >> 17127041

Modulation of CD36 protein expression by AGEs and insulin in aortic VSMCs from diabetic and non-diabetic rats.

Cristina de Oliveira Silva1, Sandrine Delbosc, Caroline Araïs, Louis Monnier, Jean-Paul Cristol, Nuria Pares-Herbute.   

Abstract

BACKGROUND AND AIM: In type 2 diabetes, the interplay between cells and inflammatory mediators up-regulates CD36 expression in macrophages. The aim of this work was to investigate advanced glycation end products (AGE)-induced CD36 expression and its regulation by insulin in aortic vascular smooth muscle cells (VSMCs) from Goto-Kakisaki (GK) rats, a non-obese insulin model of both insulin resistance and type 2 diabetes. The context of overexpression of CD36 in aortas was also evaluated. METHODS AND
RESULTS: VSMCs were isolated and cultured from the aortas of GK rats and non-diabetic rats. The expression of proteins was evaluated by Western blot. The aortic production of superoxide anion (O(2)(.-)) was measured by luminescence on isolated tissue. AGEs and advanced oxidation protein products (AOPPs) were determined in plasma by fluorescence spectroscopy and spectrophotometry, respectively. AGE receptor (RAGE), NF-kappaB, and CD36 protein expression as well as O(2)(.-) production were higher in GK aortas than in control aortas, and AGEs and AOPPs were higher in GK plasma. In VSMCs from non-diabetic rats, insulin was able to reduce (10 nM) or suppress (100 nM) the protein overexpression of CD36 induced by AGEs-BSA. In contrast, in VSMCs from GK rats, insulin was unable to reduce AGEs-BSA-induced CD36 overexpression.
CONCLUSIONS: The results suggest an overexpression of CD36 in VSMCs from GK rats and impaired control by insulin. In the context of increased plasma AGEs, aortic RAGE overexpression and increased oxidative stress markers, the data are compatible with an AGEs induced CD36 overexpression in diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127041     DOI: 10.1016/j.numecd.2006.07.008

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  12 in total

1.  CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs.

Authors:  Wei Li; Maria Febbraio; Sekhar P Reddy; Dae-Yeul Yu; Masayuki Yamamoto; Roy L Silverstein
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

Review 2.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

3.  CD36 Enhances Vascular Smooth Muscle Cell Proliferation and Development of Neointimal Hyperplasia.

Authors:  Hong Yue; Maria Febbraio; Philip A Klenotic; David J Kennedy; Yueheng Wu; Shaoxian Chen; Amira F Gohara; Oliver Li; Adam Belcher; Bin Kuang; Thomas M McIntyre; Roy L Silverstein; Wei Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

Review 4.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

Review 5.  The RAGE/multiligand axis: a new actor in tumor biology.

Authors:  Armando Rojas; Ivan Schneider; Cristian Lindner; Ileana Gonzalez; Miguel A Morales
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 6.  The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Expert Rev Mol Med       Date:  2009-03-12       Impact factor: 5.600

7.  Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy.

Authors:  L Monnier; C Colette; E Mas; F Michel; J P Cristol; C Boegner; D R Owens
Journal:  Diabetologia       Date:  2009-11-05       Impact factor: 10.122

Review 8.  CD36 as a therapeutic target for endothelial dysfunction in stroke.

Authors:  Sunghee Cho
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  Advanced Glycation End Products Impair Voltage-Gated K+ Channels-Mediated Coronary Vasodilation in Diabetic Rats.

Authors:  Wen Su; Weiping Li; Hui Chen; Huirong Liu; Haixia Huang; Hongwei Li
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

10.  Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress.

Authors:  Anca V Sima; Gabriela M Botez; Camelia S Stancu; Adrian Manea; Monica Raicu; Maya Simionescu
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.